Patents Assigned to Memorial Sloan-Kettering Cancer Center
  • Publication number: 20240123069
    Abstract: The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target uPAR and cells comprising such uPAR-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the uPAR-targeted antigen-recognizing receptors for treatment.
    Type: Application
    Filed: December 11, 2023
    Publication date: April 18, 2024
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES
    Inventors: Scott W. Lowe, Michel Sadelain, Corina Amor Vegas, Zeda Zhang
  • Patent number: 11959104
    Abstract: The presently disclosed subject matter provides for in vitro methods of inducing differentiation of human stem cells into neural crest, cranial placode or non-neuro ectoderm precursors, and cells generated by such methods. The presently disclosed subject matter also provides for uses of such cells for treating neurodegenerative and pituitary disorders.
    Type: Grant
    Filed: April 4, 2022
    Date of Patent: April 16, 2024
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Lorenz Studer, Bastian Zimmer, Jason Tchieu
  • Patent number: 11957668
    Abstract: The present technology relates to methods for treating, preventing, and/or ameliorating kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases, in a subject in need thereof. In particular aspects, the present technology relates to the use of BRAF, MEK, and/or CSF-1R inhibitors to treat, prevent, and/or ameliorate kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases.
    Type: Grant
    Filed: May 23, 2022
    Date of Patent: April 16, 2024
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Frederic Geissmann, Elvira Mass, Rocio Vicario
  • Publication number: 20240115720
    Abstract: The present invention provides a novel anti-DLL3 antibody-pyrrolodiazepine derivative and a novel anti-DLL3 anti-body-pyrrolodiazepine derivative conjugate using the same.
    Type: Application
    Filed: January 13, 2022
    Publication date: April 11, 2024
    Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: John T. POIRIER, Charles RUDIN, Jason LEWIS, Abdul KHAN, David ANDREW, Xinlei CHEN, Ivo LORENZ, Hironori MATSUNAGA
  • Publication number: 20240115721
    Abstract: It is an object of the present invention to provide an antibody-drug conjugate of an antibody binding to DLL3 and a drug having antitumor activity, a pharmaceutical composition comprising the antibody-drug conjugate and having therapeutic effects on a tumor, a method for treating a tumor using the antibody-drug conjugate or the pharmaceutical composition, and the like. The present invention provides an antibody-drug conjugate of an antibody binding to DLL3 and a drug having antitumor activity, a pharmaceutical composition comprising the antibody or the antibody-drug conjugate, and a method for treating a tumor.
    Type: Application
    Filed: January 13, 2022
    Publication date: April 11, 2024
    Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: John T. POIRIER, Charles RUDIN, Jason LEWIS, Abdul KHAN, David ANDREW, Xinlei CHEN, Ivo LORENZ, Hironori MATSUNAGA
  • Publication number: 20240117066
    Abstract: The presently disclosed subject matter provides antibodies or antigen-binding fragments thereof that bind to uPAR and methods of using such antibodies or antigen-binding fragments thereof same.
    Type: Application
    Filed: December 11, 2023
    Publication date: April 11, 2024
    Applicants: Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute For Cancer Research, Memorial Hospital For Cancer and Allied Diseases
    Inventors: Scott W. Lowe, Michel Sadelain, Corina Amor Vegas
  • Patent number: 11951331
    Abstract: Described is an approach for tracking 3D organ motion in real-time using magnetic resonance imaging (MRI). The approach may include offline learning, which may acquire signature and 3D imaging data over multiple respiratory cycles to create a database of high-resolution 3D motion states. The approach may further include online matching, which may acquire signature data only in real-time (latency less than 0.2 seconds). From a motion state and motion signature database, the 3D motion state whose signature best (or sufficiently) matches the newly-acquired signature data may be selected. Real-time 3D motion tracking may be accomplished by performing time-consuming acquisition and reconstruction work in an offline learning phase, leaving just signature acquisition and correlation analysis in an online matching step, minimizing or otherwise reducing latency. The approach may be used to adapt radiotherapy procedures based on tumor motion using a magnetic resonance linear accelerator (MR-Linac) system.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: April 9, 2024
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Jose Ricardo Otazo Torres, Li Feng
  • Publication number: 20240108705
    Abstract: The present disclosure provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to an immunoresponsive cell comprising an antigen-recognizing receptor (e.g., a chimeric antigen receptor (CAR) or a T cell receptor (TCR)), and expressing increased level of IL-36. In certain embodiments, the engineered immunoresponsive cells are antigen-directed and have enhanced immune-activating properties.
    Type: Application
    Filed: August 10, 2023
    Publication date: April 4, 2024
    Applicant: Memorial Sloan-Kettering Cancer Center
    Inventors: Anthony Daniyan, Renier J. Brentjens
  • Patent number: 11946867
    Abstract: Described herein are 3D single-molecule super-resolution imaging systems and methods. The provided systems and methods use modulation interferometry and phase-sensitive detection techniques that achieve less than 2 nanometer axial localization precision, which is well below the 5-10-nanometer-sized individual protein components. To illustrate the capability of this technique in probing the dynamics of complex macromolecular machines, (1) movement of individual multi-subunit E. coli RNA Polymerases were visualized through the complete transcription cycle, (2) kinetics of the initiation-elongation transition were dissected, (3) the conformational changes from the open initiation complex to the elongation complex were analyzed, and (4) the fate of ?70 initiation factors during promoter escape were determined.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: April 2, 2024
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Alexandros Pertsinidis, Guanshi Wang
  • Publication number: 20240100059
    Abstract: The present disclosure relates to methods of treating a vascular malformation in a subject expressing a gain-of-function mutation in a PIK3CA gene comprising administering, to the subject, an effective amount of an agent that inhibits phosphoinositide 3-kinase (“PI3K”).
    Type: Application
    Filed: April 10, 2023
    Publication date: March 28, 2024
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Eulalia Baselga, Pau Castel, Jose Baselga
  • Patent number: 11941900
    Abstract: The present application relates generally to identifying regions of interest in images, including but not limited to whole slide image region of interest identification, prioritization, de-duplication, and normalization via interpretable rules, nuclear region counting, point set registration, and histogram specification color normalization. This disclosure describes systems and methods for analyzing and extracting regions of interest from images, for example biomedical images depicting a tissue sample from biopsy or ectomy. Techniques directed to quality control estimation, granular classification, and coarse classification of regions of biomedical images are described herein. Using the described techniques, patches of images corresponding to regions of interest can be extracted and analyzed individually or in parallel to determine pixels correspond to features of interest and pixels that do not.
    Type: Grant
    Filed: April 18, 2023
    Date of Patent: March 26, 2024
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Andrew Schaumberg, Thomas Fuchs
  • Publication number: 20240091353
    Abstract: The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen recognizing receptor and one of a chimeric costimulatory receptor. Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.
    Type: Application
    Filed: June 13, 2023
    Publication date: March 21, 2024
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Christopher C. Kloss, Michel Sadelain
  • Publication number: 20240091361
    Abstract: The presently disclosed subject matter provides novel T cell receptors (TCRs) that target a mutated RAS protooncogene. The presently disclosed subject matter further provides cells comprising such TCRs, and methods of using such cells for treating cancers associated with RAS.
    Type: Application
    Filed: November 22, 2023
    Publication date: March 21, 2024
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Christopher A. KLEBANOFF, Smita S. CHANDRAN
  • Patent number: 11932690
    Abstract: The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to novel designs of chimeric antigen receptors (CARs) and engineered immunoresponsive cells comprising the same. The engineered immunoresponsive cells comprising the novel CARs are antigen-directed and have extended persistence without compromising function.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: March 19, 2024
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Michel Sadelain, Judith Feucht, Mohamad Hamieh, Jie Sun, Jorge A. Mansilla-Soto
  • Patent number: 11931425
    Abstract: Described herein is a method of induced cell death via ferroptosis by nanoparticle ingestion. Moreover, the present disclosure describes the administration of high concentrations of ultrasmall nanoparticles at multiple times over the course of treatment in combination with a nutrient-depleted environment, thereby modulating cellular metabolic pathways to induce cell death by the mechanism ferroptosis. Ferroptosis involves iron, reactive oxygen species, and a synchronous mode of cell death execution.
    Type: Grant
    Filed: December 30, 2021
    Date of Patent: March 19, 2024
    Assignees: Memorial Sloan Kettering Cancer Center, Cornell University
    Inventors: Michelle S. Bradbury, Ulrich Wiesner, Michael Overholtzer, Howard Scher, Kai Ma
  • Publication number: 20240076370
    Abstract: The presently disclosed subject matter provides antibodies that bind to GPRC5D and methods of using the same.
    Type: Application
    Filed: December 22, 2022
    Publication date: March 7, 2024
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: Renier J. Brentjens, Eric L. Smith, Cheng Liu
  • Patent number: 11921116
    Abstract: The present disclosure relates to the use of one or more biomarkers to evaluate the likelihood that a CDK4 inhibitor would produce an anti-cancer effect in a subject. Accordingly, in certain non-limiting embodiments, the present disclosure provides for methods, compositions and kits for a companion diagnostic for CDK4 inhibitors, and in particular, for the use of the colocalization of Enigma and CDH18 biomarkers to foci within the cancer for determining whether the cancer can be successfully treated by CDK4 inhibition.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: March 5, 2024
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Mary Elizabeth Dooley, Marta Kovatcheva, Samuel Singer, William D. Tap, Aimee Crago, Andrew Koff
  • Publication number: 20240067924
    Abstract: Cranial placodes are embryonic structures essential for sensory and endocrine organ development. The efficient derivation of cranial placodes from human pluripotent stem cells is disclosed where the timed removal of the BMP inhibitor Noggin, a component of the dual-SMAD inhibition strategy of neural induction, triggers placode induction at the expense of CNS fates. Further fate specification at the pre-placode stage enables the selective generation of placode-derived trigeminal ganglia capable of in vivo engraftment, mature lens fibers and anterior pituitary hormone-producing cells that upon transplantation produce hormones including, but not limited to, human growth hormone and adrenocortiocotropic hormone in vivo. Alternatively, anterior pituitary hormone-producing cells are generated in cell culture systems in vitro.
    Type: Application
    Filed: December 21, 2022
    Publication date: February 29, 2024
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Stuart Chambers, Lorenz Studer, Zehra Dincer, Bastian Zimmer
  • Publication number: 20240066148
    Abstract: The presently disclosed subject matter provides for expression cassettes that allow for expression of a globin gene or a functional portion thereof, vectors comprising thereof, and cells transduced with such expression cassettes and vectors. The presently disclosed subject matter further provides methods for treating a hemoglobinopathy in a subject comprising administering an effective amount of such transduced cells to the subject.
    Type: Application
    Filed: January 26, 2023
    Publication date: February 29, 2024
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, UNIVERSITY OF WASHINGTON
    Inventors: Michel Sadelain, Isabelle Riviere, Jorge Mansilla-Soto, Xiuyan Wang, George Stamatoyannopoulos, John Stamatoyannopoulos, Mingdong Liu
  • Patent number: 11913959
    Abstract: Provided herein are methods of treating a nonhematopoietic malignant tumor in a patient and methods of prognosing a nonhematopoietic malignant tumor in a patient, comprising administering to the patient a therapeutically effective amount of an agent that preferentially kills or inhibits proliferation or activity of leukocytes relative to nonhematopoietic cells.
    Type: Grant
    Filed: March 19, 2021
    Date of Patent: February 27, 2024
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Larry Norton, Ross Levine, Maria Kleppe, Elizabeth Comen